➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Merck
Mallinckrodt
Medtronic
Moodys

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,919,025


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,919,025 protect, and when does it expire?

Patent 9,919,025 protects NOCDURNA and is included in one NDA.

This patent has forty-two patent family members in twenty-eight countries.

Summary for Patent: 9,919,025
Title:Pharmaceutical formulations of desmopressin
Abstract: Described herein are orodispersible pharmaceutical dosage forms of desmopressin comprising desmopressin free base or a pharmaceutically acceptable salt thereof, and one or more carriers, wherein at least one carrier is hydrolyzed gelatin in an open matrix network structure. Also described are methods of making and using such desmopressin orodispersible pharmaceutical dosage forms.
Inventor(s): Nilsson; Anders (Lund, SE), Lindner; Hans (Berlin, DE), Wittendorff; Jorgen (Hvidovre, DK)
Assignee: FERRING B.V. (Hoofddorp, NL)
Application Number:15/333,503
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,919,025

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS ⤷  Free Forever Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,919,025

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0210397.6May 7, 2002
PCT/IB2002/004036Sep 20, 2002

International Family Members for US Patent 9,919,025

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 039092 ⤷  Free Forever Trial
Argentina 039794 ⤷  Free Forever Trial
Argentina 107948 ⤷  Free Forever Trial
Austria 333886 ⤷  Free Forever Trial
Australia 2002337419 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
McKinsey
Mallinckrodt
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.